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and autoimmunity by citrullinated vimentin.
Methods: The C4P-003 study included 204 symptomatic (VASpain >
10) knee OA patients (KL 1 to 4) and 71 subjects of same age and gender
distribution, with no signs of knee OA (VASpain<10, KL ¼ 0). Mean age
was 64.5 (42-80), BMI was 28.1 (18.5- 47.3) and there was 49 % female.
Following clinical outcomes were monitored; VASpain (0-10 cm),
radiographic assessment of both knees, OA functionality questionnaires
(WOMAC, EQ5D, LEQ), standard blood works (e.g. CRP), and vitals (BMI,
smoking, blood pressure). Serological biomarkers were measured by
competitive ELISA: MMP-mediated degradation fragments of type I, II
and III collagen; C1M (soft connective tissue), C2M (cartilage degrada-
tion) and C3M (ﬁbrogenesis), and MMP-generated fragment of cit-
rullinated vimentin (VICM). C2M and C1M were used as classiﬁcation
variables setting cut-offs at the medians (N ¼ 275); at 258 pmol/L and
40 nmol/L, respectively. Subjects were subdivided into quartiles: Q1,
low C2M/low C1M; Q2, low C2M/high C1M; Q3, high C2M/low C1M; Q4,
high C2M/high C1M. Kruskal-Wallis test used to compare the quartiles.
Results: Serum C1M and C2M were independent co-variables (rho ¼
0.08). When separating the subjects into quartiles the age, gender and
BMI distribution remained the same. WOMAC pain and function were
signiﬁcantly higher (p0.1). CRP as well as C3M levels were signiﬁcantly
higher (p<0.00001) in those patients with a high C1M level (Q2&Q4).
There was a tendency (p ¼ 0.079) towards lower level of VICM in
patients with both low level of C2M and C1M (Q1), as summarized in
the ﬁgure.
Conclusions: High soft tissue degradation was associated with
inﬂammation and ﬁbrosis, as validated for other disease pathologies.
However, patients with a high level of cartilage degradation, but with
low inﬂammation and ﬁbrosis experienced lower pain and better
function of their knee, indicating that cartilage degradation in itself is
independent of symptomatic OA. Patients with low cartilage and soft
tissue degradation had a signiﬁcantly lower level of citrullinated anti-
gens, reﬂecting a phenotype without an auto-immune component.
Interestingly, KL score was not associated with any of the groups.115
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Purpose: There is a great medical need for regeneration of damaged
cartilage for the beneﬁt of OA patients. Consequently, there is an intense
search for safe anabolic treatment for articular cartilage. However, there
is a lack of tools to investigate the action of anabolic pathways in
chondrocytes. This constitutes a need for biomarkers, which can
quantify cartilage formation. The aim of the study was to develop an
ELISA (ProC2), which is speciﬁc for the beta splice variant of the N-
terminal type II procollagen (P2BNP). This splice variant is expressed in
healthy cartilage, whereas the expression of the 69 amino acids longeralpha splice variant (P2ANP) is associated with embryogenesis and
cartilage pathologies. We hypothesized that the beta splice variant is
the form that is needed for regeneration/repair of mature cartilage, thus
the effect of anabolic factors should result in the release of P2BNP.
Furthermore we investigated whether the P2BNP assay was able to
detect changes in collagen formation in an ex vivo bovine full-depth
cartilage explants model (BEX).
Methods: A competitive ELISA speciﬁcally measuring P2BNP was
developed applying amonoclonal antibody raised inmouse recognizing
the N-terminus of the N-terminal propeptide of collagen type II. The
assay was technically validated. The range of the assay was 1.25-
37nmol/L (intra-assay CV 6.87%, inter-assay CV 8.92%). Tests of linearity
and analytic sensitivity, speciﬁcity, and stability of human amniotic
ﬂuid, fetal bovine serum (FBS) and human serum from women over 60
years were evaluated in the assay. After coating streptavidin plates with
biotin-QDVRQPG samples were added together with the antibody. The
plates were thereafter incubated with EnVision. Tetramethyl benzini-
dine (TMB) was added. The TMB reactionwas stopped by adding H2SO4
and measured at 450 nm with 650 nm as the reference.
The BEX explants (approx. :12mg) were isolated from the femur condyle
and cultured for 3 weeks in serum free DMEM/F12 medium with 3
weekly changes. Supernatant was collected. Following anabolic factors
were applied: transforming growth factor (TGF)-b, ﬁbroblastic growth
factor (FGF)-2, and insulin like growth factor (IGF)-1 each in concen-
trations of 100, 10, 1, 0.1, 0.001ng/ml. Data are shown as mean [95%-CI]
or (SD). Two tailed Mann Whitney test was used to compare bars with
vehicle. The viability of the explants was tested by Alamar blue prior to
cytokine stimulation and at termination.
Results: The ProC2 assay was sensitive and speciﬁc for human/bovine
N-terminal of the procollagen type II seen by a 100% inhibition of the
signal with 150nmol/L selection peptide: peptides with the corre-
sponding rat/mouse or the human alpha splice variant sequence could
not displace the signal. High levels of P2BNP was quantiﬁed in human
amniotic ﬂuid (163-187,7nmol/L) and FBS (851-901nmol/L) and showed
excellent linearity (dilution range 1:2-1:64 and 1:20-1:160 with 100%
(SD 7.6) recovery). In contrast, serum P2BNP levels in the elderly
women were below the lower detection limit. No signiﬁcant matrix
effect was observed in serum or conditioned medium. In the medium
from BEX, it was found that TGF-b and IGF-1 signiﬁcantly induced
secretion of P2BNP in a dose-dependent manner compared to the
untreated (ﬁgure). This association was not seen when explants were
stimulated by FGF-2.
Conclusion:To our knowledge this is the ﬁrst assay which is able to
evaluate P2BNP excretion. The ProC2 assay seems to be a promising and
novel marker of collagen type II formation. The assay was both sensitive
and speciﬁc for the beta-splice variant of collagen type II. In addition the
assay was able to differentiate between P2BNP level in supernatant of
BEX explants stimulated by either TGF-b or IGF-1 compared to
untreated.116
MAGNETIC COLLECTION OF CTXII FROM SMALL VOLUMES OF
SYNOVIAL FLUID
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Purpose: Molecular biomarker analysis in urine and serum has dem-
onstrated potential to diagnose osteoarthritis (OA) at an earlier stage
than traditional radiographic scans. Recent studies in horses suggest
biomarker analysis in synovial ﬂuid may detect OA changes prior to the
serum and urine analysis of the same biomarker. Clinically and in large
animals, synovial ﬂuid can be acquired through joint aspiration; how-
ever, the development of OA biomarkers in small animal models is
